ArticleCureus2024
Understanding De Novo Bupropion-Induced Psychosis and Its Management Strategies: A Case Report and Literature Review.
Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Dose-related Manic Switch with Psychotic Features Following Bupropion Titration: A Case Report.Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology · 2026Article
- Brexpiprazole for Agitation in Patients with Alzheimer's Dementia with and without Co-Occurring Psychosis: Post Hoc Analysis of Short- and Long-Term Trials.Neuropsychiatric disease and treatment · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Psychotic manifestations of iatrogenic origin are common in clinical practice, and it is essential to rule out organic and iatrogenic causes before attributing symptoms to psychiatric disorders. Bupropion, an atypical antidepressant used for treating depression and aiding smoking cessation, has been linked to rare instances of psychosis, especially in patients with risk factors like substance use, older age, or history of head trauma. This report describes the case of a 52-year-old man with recurrent depression who developed a bupropion-induced psychotic episode following an increase in dose to 300 mg/day. He presented with persecutory delusions, although he had no history of psychosis or contributing factors. With the withdrawal of bupropion and the addition of risperidone, the patient's psychotic symptoms resolved within a week. The report takes a look at the recent literature since 2010 and the role of bupropion's dopaminergic effects, its ability to lead to psychosis, and the risk factors associated with this problem. Although there are no guidelines, in some cases antipsychotics such as risperidone have been helpful in reversing bupropion-induced psychosis after discontinuation of the drug.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.